# OnCo record paper-stampede-abiraterone-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-stampede-abiraterone-nejm-2017" ;
  schema:name "STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer"@en ;
  schema:description "Giving the hormone-pathway drug abiraterone from the start, alongside standard testosterone suppression, cut deaths by more than a third in men newly diagnosed with high-risk or metastatic prostate cancer."@en ;
  schema:url <https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1702900>, <https://clinicaltrials.gov/study/NCT00268476> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1702900> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "James ND, de Bono JS, Spears MR, et al." ;
  onco:related <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/> ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:institutions <https://onco.cc/institutions/icr-london/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/cruk/> ;
  onco:terms <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/standard-of-care/> ;
  onco:people <https://onco.cc/people/nicholas-james/>, <https://onco.cc/people/johann-de-bono/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-generic-repurposing/> ;
  onco:journals <https://onco.cc/journals/nejm/> .